pa health & wellness

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.



Plan: PA Health & Wellness	**Submission Date: 09/01/2019**
Policy Number: PHW.PDL.034	**Effective Date: 01/01/2020** **Revision Date: 09/01/2019**
Policy Name: Immunomodulators, Atopic Dermatitis	

Type of Submission – Check all that apply:

- ☐ **New Policy**
- ☐ **Revised Policy***
- ☐ **Annual Review - No Revisions**
- ✓ **Statewide PDL -** *Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.*

***All revisions to the policy must be highlighted using track changes throughout the document.**

Please provide any changes or clarifying information for the policy below:

New Policy created.

Name of Authorized Individual (Please type or print):	**Signature of Authorized Individual:**
Francis G. Grillo, MD	Francis Gregory Grillo M.D

Clinical Policy: Immunomodulators, Atopic Dermatitis

Reference Number: PHW.PDL.034
Effective Date: 01/01/2020
Last Review Date: 09/01/2019

Revision Log

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health and Wellness® that Atopic Dermatitis Immunomodulators are **medically necessary** when the following criteria are met:

I. Requirements for Prior Authorization of Immunomodulators, Atopic Dermatitis

A. Prescriptions That Require Prior Authorization

Prescriptions for Immunomodulators, Atopic Dermatitis that meet the following conditions must be prior authorized.

1. A non-preferred Immunomodulator, Atopic Dermatitis.

2. A prescription for Eucrisa (crisaborole topical).

B. Review of Documentation for Medical Necessity

In evaluating a request for prior authorization of a prescription for an Immunomodulator, Atopic Dermatitis, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. **For Dupixent** (dupilumab), refer to PHW.PDL.737.01 Dupixent (dupilumab); **OR**

2. **For a non-preferred topical calcineurin inhibitor**, has a documented history of therapeutic failure of, a contraindication to, or intolerance of the preferred topical calcineurin inhibitors; **AND**

3. **For Eucrisa (crisaborole topical)**, both of the following:

   a. Has a documented history of therapeutic failure of, a contraindication to, or intolerance of a topical calcineurin inhibitor; **AND**
   b. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed literature.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

pa health & wellness

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Immunomodulator, Atopic Dermatitis. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. **Approval Duration:**
- **New request: 6 months**
- **Renewal request: 12 months**

Reviews, Revisions, and Approvals	Date
Policy created	01/01/2020